Fig. 2
From: NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Anti-NG2 MoAb lacks both cellular-mediated (ADCC) and complement-mediated (CDC) cytotoxicity. a CD19, CD20, and NG2 surface immunophenotype in Daudi (control) and SEM-NG2 cells. b, c CDC (b) and ADCC (c) assays at 4 h (left panels) and 24 h (right panels) with Daudi and SEM-NG2 cells using both anti-NG2 (7.1 MoAb) and anti-CD20 (Rituximab) (n = 2). CT: no MoAb control. Human AB serum was used for CDC and human PBMCs were used for ADCC. *p < 0.05; **p < 0.01; ***p < 0.001
